Contemporary technological advances in laboratory medicine have led to a category of laboratory diagnostics known as laboratory developed tests (LDTs). LDTs are defined as a subset of in vitro diagnostics (IVDs) that are "intended for clinical use and designed, manufactured and used within a single laboratory." 1 In recent years, the US Food and Drug Administration (FDA) has identified problems with several high-risk LDTs and has cited concerns that "patients could initiate unnecessary treatment, delay or forego treatment altogether." 1 In addition to the FDA, other governmental agencies and private organizations have challenged the validity, accuracy, oversight, and safety of LDTs. The FDA has now proposed requiring "all in-vitro diagnostic (IVD) tests intended for use in drug or biologic therapeutic decision-making be held to the same scientific and regulatory standard" as medical device firms. 2 Since medical device development is held to a stringent and lengthy regulatory approval process, there is significant apprehension regarding the potential for undue delays in test development and patient access should LDTs be held to the same standard. Unlike the medical device industry, which is subject to the requirements of the FDA, clinical laboratories are under the jurisdiction of the Centers for Medicare & Medicaid Services (CMS) and the Clinical Laboratory Improvement Amendment (CLIA). The FDA has proposed that laboratories adopt a formal risk-based classification and approval process, quality system regulation (QSR), and a formalized design control structure, as described in its 2014 draft guidance entitled Framework for Regulatory Oversight of Laboratory Developed Tests. 1 In this draft, the FDA proposes directives that are currently not mandated by CLIA or any other regulatory agency regarding laboratory oversight. Following a period of public comment, the FDA announced, in a Discussion Paper dated January 13, 2017, that it was considering possible alternatives to the original framework proposal. 3 Laboratories continue to struggle to understand the implications of this additional regulatory oversight and their responsibility to comply in the event the draft guidance becomes policy. In addition, for those laboratories licensed by the New York State Department of Health (NYSDOH), the Wadsworth Center's Clinical Laboratory Evaluations Program (CLEP) has recently adopted a three-tiered, risk-based review and approval policy for all LDT submissions, effective November 14, 2016. Risk stratification is based on an algorithm guided by three criteria: (1) well-established method, (2) key determinant of care assessment, and (3) the potential for patient impact. 4 It is interesting to note that in its recent Discussion Paper, the FDA suggests the possible use of third-party collaborators, including the NYSDOH CLEP for review of LDTs. The FDA indicates that it is "exploring accepting NYSDOH review in lieu of its own." 
Motivation for the Research
The motivation for this research is to educate the laboratory community pertinent to LDTs by introducing terms, definitions, and regulatory requirements and discuss the QSR as proposed by the FDA. We compare the requirements of the 21 CFR 820 with the recommended Clinical Laboratory Standards Institute (CLSI) 12 Quality System Essentials (QSEs) for laboratories to understand how these principles may be incorporated and translated into laboratory processes that align and support the QSR. We also explore "design control" and discuss how these requirements for the medical device industry may be applicable to laboratory testing. We conducted interviews with laboratory professionals to gain an understanding of their concerns regarding the FDA draft guidance and translated that feedback into operational factors relevant for the development of a robust quality management system. Finally, we tested the factors for functionality, agility, and usefulness through a survey and propose the design of a framework to assist laboratories prepare in the event the 2014 draft guidance becomes a policy.
Contribution
This article contributes to the discussion about LDTs by serving as a proactive call for action by educating laboratory professionals and providing the impetus to move from a wait-and-see approach to insight, knowledge, and clarity that encompass the many facets of LDTs. We construct a means to collect substantiated data regarding the needs and gaps in laboratories and propose translation of those objectives into a vocabulary familiar to laboratorians. Finally, we translate and validate functionality and usefulness of strategic factors for design of a robust regulatory quality management system (QMS) by voice of the customer.
Background
The literature provides a rich background regarding the history of LDTs. The FDA, other governmental agencies, and private firms have challenged the validity, accuracy, oversight, and safety of laboratory testing. In 2008, Genentech, a private medical device manufacturer firm of oncologic pharmaceuticals and laboratory reagents, disputed laboratories or other companies selling LDTs or making statements without sufficient scientific evidence to support such claims. 5 Genentech petitioned the FDA to "require all in-vitro diagnostic (IVD) tests intended for use in drug or biologic therapeutic decision-making be held to the same "scientific or regulatory review." 5 Since 2008, the FDA has identified problems with several high-risk LDTs; however, many organizations have objected to the FDA's oversight of LDTs, including the American Hospital Association, the American Cancer Institute, and the American Clinical Laboratory Association (CLA). The American Medical Association has stated that "the FDA proposal will add an additional layer of regulatory requirements which may result in patients losing access to timely lifesaving diagnostic services and hinder advancements in the practice of medicine." 6 Certain professional organizations argue that the FDA lacks jurisdiction over LDTs, and the CLA has argued, "The FDA requirements will stifle innovation and slow patient access to critical diagnostics." 6 Moreover, the academic laboratories, if held to the 21 CFR 820 standard, may be required to perform clinical trials for each new genetic test developed. This process would require additional resources, and as explained by Evans and Watson, 7 "Laboratories have insufficient resources to meet the proposed requirements and would essentially be precluded from developing or even improving tests in response to patient needs, clinician demands and changing technology."
The FDA was given oversight and authority over in vitro diagnostic medical devices in 1976; however, regulatory oversight for laboratories remains with CLIA. 
Regulatory Overview

CLIA
In this section, we highlight some of the important regulations that have led to the current framework governing LDTs. First, we discuss CLIA, the medical device amendment, and the FDA quality system regulations, and then we compare how those regulations differ from laboratory accreditation.
The clinical laboratory has undergone progressive regulation over the past several decades, with key milestones depicted in ❚Figure 1❚. The current regulatory framework has evolved from the CLIA of 1967 and 1988 and is enforced under the direction of the CMS. The initial intent of the CLIA 1967 amendment was to establish licensing requirements for laboratories across state lines; however, the legislation for CLIA '88 was established to update requirements, implement performance measures, and add personnel responsibilities. Since 1988, the amendment has progressed to ensure validity, reliability, accuracy, and appropriateness of clinical laboratory testing and results. 9 Although the aim of CLIA is to ensure that clinical laboratories operate suitably, 10 Burd 10 explains that CLIA lists the performance specifications as described in CFR 493 to be established but "does not specify the scientific methodology or implementation tool to be used." CLIA instead defers selection of the appropriate method meeting these performance specifications to the laboratory director's judgment. Useful resources include not-forprofit agencies, such as the CLSI, the College of American Pathologists, and the International Organization for Standardization, which develop and recommend clinical laboratory standards and accreditation criteria. 10 To this end, the CLSI has recommended implementation of 12 QSEs ❚Table 1❚ as a "framework to a systems approach to managing quality." 11 The adoption of all 12 QSEs will better ensure safe testing practices that align with governmental regulations.
Medical Device Amendment
The medical device amendment was established in 1976 after 4.5 million Dalkon Shield intrauterine devices sold between 1971 and 1974 adversely affected 900,000 women in the United States. 12 This device, which was considered faulty, was the impetus that promoted the establishment of FDA regulatory oversight to ensure the effectiveness of the intended use of medical devices and to verify safe manufacturing practices. The amendment required three classifications of medical devices: class I, low-risk medical devices; class II, moderate risk; and class III, high risk. The regulatory approval process differs significantly for each class of device. Class I devices require general controls, class II devices require premarket notification (510(k)), and class III devices require the most rigorous process of premarket approval (PMA). These classifications of medical devices had not been a concern for diagnostic laboratories until the FDAs announced the 2014 draft guidance for LDTs.
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QSR (21 CFR 820)
The 21 CFR 820 or QSR is a regulatory requirement that directs the methods for the design, manufacture, packaging, labeling, storage, installation, and servicing of medical devices to ensure their safety and efficacy. 1 The QSR encompasses organizational structure, management responsibilities, procedures, processes, and resources for establishing and maintaining a quality management system and serves as a guide for organizations. The 2014 LDT draft guidance proposes the use of this existing QSR. However, LDTs differ from medical devices in three respects: (1) LDTs are considered by most outside of the FDA to be a medical service, not a device; (2) medical devices may be tested on human participants, and approvals may require additional time, processes, resources, and regulatory requirements 
Comparing QSE to QSR
Parallel to the QSR, the 12 QSEs contain most of the broad management categories and elements found in the 21 CFR 820 (❚Table 3❚ is a side-by-side comparison of QSE to QSR, showing where they are equivalent and how they differ). 11, 22 However, the extent of their applicability to laboratories differ. Without a step-by-step guide for establishing the operational structure required to comply with the QSR, laboratories may feel they lack the resources and funding to develop a quality management program that meets FDA specifications.
CFR 820: Understanding Design Control
"Design control" was originally established as a guiding methodology for the design, development, manufacture, and production of medical devices to ensure that accuracy, reliability, and quality are consistently built into every new device. The elements of 21 CFR 820 design control provide the manufacturing expectation of the FDA to produce a safe and effective product. 16 This method is an iterative process similar to the product development method, and although historically intended as a requirement for medical devices, the development of policies, procedures, and processes as applied to test design should help with the establishment of design control specific to the laboratory. ❚Figure 2❚ lists each element of design control from development to design history, and ❚Table 4❚ lists each element of design control with a modified description for the practical application to organizational processes. 16, 17, 22 
Verification
Confirmation is made, through the provision of objective evidence, that specified requirements have been fulfilled (design output meets the design input requirements).
Validation
Confirmation is made through the provision of objective evidence that the requirements for a specific intended use or application have been fulfilled.
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Research Method
Now that we have covered the regulatory background, we turn to the technique conducted in this study as a mixed-method approach to research employed in two sequential phases: phase I consisted of qualitative interviews to capture the understanding of laboratory In addition to the interviews, proceedings from the 2-day FDA workshop, "Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)," 20 held January 8-9, 2015, also contributed to this study. The intent of the workshop was for the FDA to provide the rationale for the 2014 draft guidance, as well as invite feedback and participation from peers within the laboratory community to state their case for or against the 2014 framework in the context of the proposed regulatory requirements. The interview and workshop information assisted the researchers in identifying factors that would serve as the building blocks for a regulatory laboratory framework.
During phase II, a quantitative survey was conducted to test the factors identified during the interviews to determine agility, functionality, and usefulness as a proxy in the absence of implementation in a live environment.
The study was designed as follows:
Phase I-Interview A qualitative phone interview protocol was designed based on results of a review of the literature and was initially conducted to explore the potential challenges and constraints for laboratory compliance to the 2014 draft guidance. A convenience sampling strategy was used to select subject matter experts well versed in the historic, political, and practical perspective of LDTs. The nine interview participants selected were professionals from the fields of laboratory, regulatory, accreditation, and medical device segments of the industry and who had the time or the availability to participate. The names of the interviewees and associated organizations are retained as confidential.
Secondary Data
The presentations obtained from the two-day FDA workshop in 2015 pertaining to QSR were documented, described, and incorporated in this research. The public workshop was particularly helpful for this research and clarified issues and concerns as well as provided insight about future regulatory direction, produced a strategy, and explained how FDA recommendations may affect future laboratory operations.
❚Figure 2❚ All steps throughout the process of design controls as stated in 21 CFR 820 quality system regulation.
❚Table 4❚ Description of Design Control
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Step
CFR 820 Design Control Description
Design and development planning
Procedure: Set of processes that transforms requirements for an object into more detained requirements, such as the plan, design, development, execution, involvement, and interface with different groups and responsibility (ISO 9001). 2 Design input Procedure: Product characteristics, requirements, intended use, user needs, and the process to manage and resolve discrepancies are defined. The process includes responsibility approval, documentation, and rationale at every step. 3 Design output Procedure: The output consists of technical, performance, specification, and verification that the design successfully transferred into the testing environment. 4
Design review Procedure: Describes the process to review all phases of the design with documentation and approval all at each step. Establish and maintain procedures for the identification, documentation, validation, verification, review, and approval of design changes before implementation. 5 Design verification a Procedure: Describes the process that will ensure the test is safe, is effective for use, conforms to the needs of the user, and meets its intended use. The process to ensure the design works as intended has been verified, documented, and approved at each activity. 
Constructing the Interview Protocol
The interviewees were asked the questions in the following protocol and were encouraged to discuss their knowledge of LDTs. The 30-minute confidential interview protocol consisted of nine questions ❚Table 5❚.
Data Collection
The interviews were conducted by telephone over a 2-year period from April 2015 to May 2017. The process was explained prior to the interview and audio-recorded when possible, and the results were compiled. In addition to interview data, secondary data were collected from discussions that pertained to the quality system regulation during the public workshop to capture concerns with the 2014 draft guidance.
Data Analysis
The interviews were conducted with nine participants, and the discussions were manually transcribed. The topics of the conversations were tallied for frequency and coded manually. As depicted in ❚Table 6❚, the interview and secondary data were categorized into codes and subcodes, and a relational analysis was conducted to identify patterns of the most frequent theme and trends in both the interviews and the workshop discussion.
Phase II Survey: Testing the Functionality of the Framework
Constructing the Survey Protocol
A confidential Qualtrics Survey consisting of three sections was developed for this study. Section I includes survey statements derived from extensive literature searches, the qualitative interviews, and a review of the 2-day FDA workshop in 2015 pertinent to the QSR on LDTs. Based on feedback, we translated the findings into a taxonomy comprising eight strategic factors and 40 statements that serve as building blocks for a laboratory regulatory quality management system. As depicted in the supplement (all supplemental materials can be found at American Journal of Clinical Pathology online), each statement contains five statements totaling 40 outcomes ranked on a 5-point Likert scale from "extremely important" to "not important at all."
The strategic factors identified are as follows: 
Data Collection
The quantitative survey was distributed to 767 laboratory professionals from April to July 2017. The respondents included all attendees from the Executive War College Laboratory Conference held in May 2017 in New Orleans, Louisiana. The survey was also distributed to randomly selected laboratory professionals demonstrating expert knowledge regarding the field of LDTs from LinkedIn with titles in the fields of regulatory, quality, and medical laboratory.
Survey Demographics
The responses from the Qualtrics survey resulted in 51 started surveys and 35 completed surveys, with a 69% completion rate of those who responded to the survey. The respondents included 10 senior leaders, four medical directors, 13 quality professionals, two technical supervisors, one manager, and five other professionals. To ensure the appropriate expertise in the field of LDTs, each participant was asked a critical qualifying question: Do you consider yourself a subject matter expert in the topic of LDT? The participants responded as follows: "definitely yes" (n = 9), "probably yes" (n = 9), "might or might not" (n = 6), "probably not" (n = 7), and "definitely not" (n = 2), as depicted in ❚Figure 3❚.
Data Analysis
The statistical software SPSS Version 24 (SPSS,
Principal Axis Factoring Extraction Method
The data were further analyzed by the principal axis factoring extraction method-more specifically, principal component analysis with the rotation method: varimax with Kaiser normalization. According to Williams et al, 21 isolating factors with high loadings can reduce the variables into a smaller set of factors, remove variation, and cluster the relationships into patterns. This method was helpful to identify patterns consisting of high loadings with significant factors and statements exceeding 0.623, as depicted in ❚Table 7❚.
t Test
The t test was performed to determine whether the means of experts and nonexperts had distinct, differing priorities and were statistically different regarding the adoption of a QMS. Since the participants rated four of five factors within leadership commitment as the most relevant category, the assumption was the experts may have answered the statements differently due to their roles and responsibilities within the organization. The nonexperts were operationally oriented rather than occupying a leadership role. To test this assumption, the data were analyzed to determine if experts and nonexperts chose statements within the eight strategic factors differently.
Open-Ended Questions
The responses to the open-ended questions were analyzed using SPSS Version 24 to determine the number of participants considered an expert ( Figure 3 ) and to tally acceptability and satisfaction with the suggested factors as explained in the survey results section. 
Results
Interviews
The tone expressed by the interviewees was ambiguity and uncertainty regarding all aspects of the LDT process, and similar concerns were articulated, including (1) risk classification, (2) process validation to ensure the accuracy and precision of tests results, (3) ambiguity of the 21 CFR 820 requirements translated to the laboratory, (4) lack of clarity from the FDA and other governmental agencies (eg, CMS), (5) patient safety concerns of the FDA, and (6) lack of clarity and direction regarding the 2014 draft guidance.
The lack of coordination, clarity, and guidance from CLIA and the FDA has created confusion and a lack of motivation on behalf of the laboratory community. The general feedback received through the interviews showed substantial ambiguity across laboratory professionals regarding terms, definitions, and how to transfer operational requirements into regulatory terms. In addition, it is unclear how the draft guidance would translate from medical device to the laboratory. The development of a laboratory application of 21 CFR 820 quality systems regulation that would meet the LDT manufacturing requirements has not been addressed by regulatory agencies and has left laboratory leaders unprepared to be proactive. Ambiguity also existed during the interviews regarding the definition of design control and how to appropriately address and translate these requirements into the laboratory environment.
Interview Results
The discussion with the interviewees was instrumental to gain an understanding of the challenges faced by ❚Figure 3❚ Laboratory developed test (LDT) expert classification of survey respondents using question 12: do you consider yourself a subject matter expert on the topic of LDT? 
Secondary Data
FDA Public Workshop
The information shared during a 2-day FDA webinar held January 8-9, 2015, made a significant contribution to this research. 20 The FDA began the conference by addressing areas of concern regarding the overview of the LDT draft guidance and the implication of adverse test results for the patients and the laboratories, as well as how the guidance would affect regulatory agencies already lacking appropriate resources. The director of the Centers for Devices and Radiological Health, Jeffrey Shuren, stated that the "FDA is transparent and does not claim they got it all right and some say they didn't get anything right." However, the FDA is acting on the behalf of patient safety, which has made its way into the popular press. 20 In fact, adverse patient safety concerns associated with LDTs were published in the New York Times on August 28, 2008, July 7, 2011, and January 22, 2011.
Guest speakers shared their support and apprehension of the draft guidance and addressed the importance of test accuracy for appropriate therapies. Katherine Tynan, a presenter, stated, "Quality systems vary significantly in terms of scale and complexity, and one of my concerns with the current dialogue between the FDA and laboratories developing LDTs is that quality means very different things to the stakeholders." 20 Research and development firms stressed the importance of laboratories outside of manufacture to be held to the same regulatory oversight and stated that a major cause of the inaccuracies of laboratory test development is improper design and lack of validation to verify the result is as intended. This topic was substantiated by consistent feedback mentioned 12 times from all nine interviewees, who also expressed test validation concerns. Liz Lison, president of Advocea Consulting firm and a conference speaker, explained, "Most of the failures that I have seen in LDTs may have been averted if design controls had been in place. Therefore, I urge the agency not to delay the enforcement of design controls for highrisk tests and potentially introduce a two -tier system for pre-market review." 20 The oversight of laboratory testing remains with CLIA. However, a gap exists regarding the regulation of test development. Due to the advances in genomic medicine, the interviewees expressed that the oversight by CLIA is no longer adequate to manage the compliance needs of laboratories. There is a significant difference in the oversight of the FDA and CLIA. The FDA does not mandate the operation of testing as stated in CFR 493; CLIA does not ensure the safety and effectiveness of test protocols as described in 21 CFR 820. 20 
Interpretation of Findings
The interview and secondary findings validated the motivation for this study ❚Figure 5❚. The laboratory professionals illustrated the struggle to understand how to develop and organize a framework adaptable to their organization. The participant response from the 2-day ❚Figure 4❚ The results of nine interviews with laboratory developed test (LDT) experts from the field of regulatory, accreditation, diagnostic laboratory, and medical device. workshop was more directive and outlined the need of laboratories vs the uncertainty noted during the interviews. As a result, the participants substantiated the need for a regulatory vocabulary translated to operational laboratory terms. In addition, the feedback describing gaps in processing was instrumental to the development of strategic factors developed from interview and workshop feedback and proposed as the precursor to a quality systems framework that would serve as the foundation for LDT development, as depicted in ❚Table 8❚.
Survey Results
Exploratory Factor Analysis and Factor Reliability
The factor analysis was conducted to explore the data set, determine the importance of the relationships between the variables, and isolate the factors with high loadings to reduce variables into a smaller set of factors. As described by Williams et al, 21 an appropriate factor loading of 0.50 is optimal for factor analysis. However, due to the smaller sample size, a significant factor loading would be 0.60 or larger. The analysis eliminated 17 variables with smaller loadings, as shown in ❚Table 9❚. The loadings analyzed and clustered the relationships into patterns. The clusters illustrated the importance of leadership, clinical validity, process validation, and procedures to provide guidance for accuracy and consistency of processes. The weak factors removed clarified the reluctance to perform a preassessment of the existing operation to determine if the organization was prepared to operate within a regulatory environment.
Overall Mean of Categories
To determine if factors were viewed differently by experts vs nonexperts, the aggregate mean for the items associated with each factor was analyzed. As shown in ❚Table 10❚, experts vs nonexperts chose similar responses for all statements within the survey from an average of close to 1 (extremely important) to slightly over 2 (very important). This result suggests both groups considered all factors to be equally important for the development of a QMS.
t Test Factor Analysis ❚Table 11❚ shows the results of all statements chosen from experts vs nonexperts with corresponding means. Both groups choose the options of (1) extremely important and (2) very important statements, resulting in consistency and a small variance between all responses. The hypothesis was that experts and nonexperts had different and distinct priorities regarding adoption of a QMS due to their roles and responsibilities within the organization and may have answered statements differently. We found that there was no significant difference between experts and nonexperts on average importance attributed to the strategic factors (Table 10 ).
Survey Results: Expert Response per Quartile
All participants agreed that leadership commitment was extremely important as illustrated by top ranking statements 1, 2, 3, and 5 with corresponding means from 1.3 to 1.48 (Table 7) . The commitment Interview topic Leaders are unclear regarding how 21 CFR 820 requirements apply to laboratory testing considered by many to be a service, not a product.
Leadership commitment
Interview topic Laboratories lacked the rigor that is present in the manufacture of medical devices. Training FDA public workshop
It is essential that the FDA harmonize the QSR requirements with CLIA requirements at a more granular level to prevent duplicate efforts and to ease the regulatory burden because governmental agencies have not provided the necessary guidance for struggling laboratories.
Preassessment of the existing quality management system
FDA public workshop
Laboratory failures due to lack of process control Design control
Change is necessary to raise the level of quality, prioritize tasks, and dedicate the time and resources necessary to understand regulatory requirements to attain process standardization.
Document control
Interview topic The major cause of the inaccuracies of laboratory test development is improper design and lack of validation to verify the result is as intended.
Process control
FDA public workshop
Laboratories need guidance documents and a defined process to simplify and translate the FDA proposal.
Development of a QMS framework Interview topic
The importance of test systems to validate protocols, processes, and test development that will consistently ensure the effectiveness and accuracy of test results
Process validation
CLIA, Clinical Laboratory Improvement Amendment; FDA, US Food and Drug Administration; QMS, quality management system; QSR, quality system regulation. of leadership to institute key performance indicators, conduct direct regulatory initiatives, and maintain and consistently communicate change in the organization was considered significant. However, a poorly rated statement was the task of an organizational preassessment to determine missing processes, lack of procedures, and deficiencies and create a list of necessary guidance documents to comply with regulatory requirements. This outcome was unanticipated due to laboratory accreditation agency practices of a crosswalk between laboratory current processes in comparison to requirements. Statements depicting design control were not considered extremely important, with all five statements located on the second, third, and fourth quartile, despite the proposal for QSR by the FDA. There were no significant results for the following statements: (1) the statement suggesting a procedure to address the process for identification, documentation, and reporting of an adverse event in the laboratory and the (2) establishment of an LDT quality committee to quickly approve changes and provide support. Note: Mean scores with identical values may fall within the same placement across several categories of strategic factors.
Respondent Feedback
Open-ended questions were presented to the survey respondents in question 9: "Do you agree with the strategic factors identified in the proposed framework for Quality Management System of LDTs? If not, please suggest additional factors pertinent to develop a robust framework." This question resulted in positive feedback for the development of a QMS framework, and 20 of 35 participants agreed with the strategic factors proposed by the researcher. The respondents agreed that all the factors and statements listed were indeed important. However, leadership buy-in was considered imperative for implementation and to ensure the proper resources to address development of the QMS.
Feedback: The Establishment of a QMS Framework
The following questions were presented to the survey respondents in question 10: "Do you think the establishment of a Quality Management System framework will assist LDT laboratories incorporate regulatory requirements such as design control more readily? If not, why and what else is necessary?" Out of 35 respondents, 23 answered this question with yes, I agree and strongly agree, and nine of 35 respondents scripted favorable feedback. The respondents agreed that a fully functional QMS is needed to meet accreditation requirements, and document control is critical in this process. An accepted framework will provide the laboratory community with "structure, uniformity and integrity" (survey respondent) and the documentation discipline for all laboratories. The process is not only beneficial for the development of LDTs but in the general laboratory as well to comply with accreditation requirements. A crosswalk of each clause of Part 21 CFR 820 can be performed in comparison to the elements of each QSE. The QSE can be used as the QMS © American Society for Clinical Pathology framework; however, the most difficult topic discussed in the draft guidance is clinical significance and how the results derived from an LDT are being used or will be used to guide therapy.
Discussion
The impetus for change within the laboratory community began with the awareness of patients who were adversely affected by the results of LDTs. Historically, the design and development of LDTs were not under the jurisdiction of CLIA, and testing operations are formally not within the oversight of the FDA. Many articulated that the FDA has no jurisdiction over LDTs. In addition, before synergistic legislation can occur, the agencies must bridge the gap between required regulations. Shelia Walcoff of Goldbug Strategies and an FDA workshop speaker stated, "It is essential that FDA harmonize the QSR requirements with CLIA requirements at a more granular level to prevent duplicate efforts and to ease the regulatory burden" because governmental agencies have not provided the necessary guidance for struggling laboratories. 20 The adoption of a laboratory structure that would satisfy accreditation and regulation requirements in the event the 2014 draft guidance becomes a policy is perplexing. The interviewees expressed that laboratories may be required to change business strategies, outsource, or terminate many of the current tests if the FDA proposal becomes a policy.
However, interviewees also expressed that laboratory leaders are taking the wait-and-see approach because the laboratory community considers test development a service, not a product. The interviewees shared their concerns about CLIA and the FDA collectively developing standards and guidance documents prior to a policy release. The current regulations for medical devices include requirements for design control geared for product development, and the meaning of design control, methodology, and the translation of these regulations from the medical device industry to a clinical laboratory do not exist. The survey respondents agreed that a regulatory-oriented framework for the development of LDTs is needed in the laboratory, and it is interesting to note that the survey respondents did not consider design control as extremely or very important despite the proposal for a QSR by the FDA. These findings support the conclusion of ambiguity in interpreting the meaning of design control and how this requirement would be adapted to the laboratory environment. Liz Lison, president of Advocea Consulting firm and a FDA workshop speaker, explained, "Most of the failures that I have seen in LDTs may have been averted if design controls had been in place." 20 The eight suggested strategic factors and 40 statements derived from the literature, qualitative interviews, and the FDA workshop provide the impetus for the design of an QMS. The respondents agreed with all statements relevant to the design of a QMS based on needs and gaps expressed by laboratory professionals. This finding aligns with the results of the survey as there was no significant difference in the way the experts vs nonexperts responded to factors and associated statements. All respondents chose statements as extremely important or very important. This finding directly aligns with the recommendation by Katherine Tynan, an independent regulatory consultant from the 2015 FDA workshop, who offered advice to governmental agencies as follows:
1. "Develop a common vocabulary that laboratories can understand." 2. "Simplify the cumbersome QSR and assist laboratories translate the directives." 3. "Develop a "QSR fit for purpose and harmonize the standard."
Tynan's advice to laboratories was to "invest in a quality management system, implement all factors of design control, and be proactive and prepare for future regulatory requirements." 20 Consequently, the preparation of a QMS requires the understanding of where gaps exist to develop appropriate processes that would adhere to requirements. Moreover, this survey statement suggesting review of current policies and procedures to identify gaps was not considered important by all groups. This was an interesting conclusion because this is general practice within laboratory accreditation agencies.
The future research includes design of an agile, robust quality management system that will incorporate the suggested factors as follows: leadership commitment, training, preassessment, design control, document control, and development of a QMS framework. 
